Stock comparison
Indivior Pharmaceuticals
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
INDV
Indivior Pharmaceuticals
Market cap
$4.68B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | INDV | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 35D | 69B | MTD |
| Benjamin Graham | 30F | 65B | MTD |
| Philip Fisher | 44D | 63C | MTD |
| Peter Lynch | 71B | 66B | INDV |
| Joel Greenblatt | 78B | 68B | INDV |
| Charlie Munger | 50D | 74B | MTD |
| Terry Smith | 46D | 70B | MTD |
Side-by-side metrics
| Metric | INDV | MTD |
|---|---|---|
| Market cap | $4.68B | $22.29B |
| P/E (TTM) | 19.0x | 25.3x |
| EV/EBIT | 19.1x | 21.6x |
| ROIC (TTM) | 85.68% | 36.09% |
| Gross margin | 83.11% | 57.79% |
| Net margin | 19.44% | 21.4% |
| Revenue CAGR 5y | 11.87% | 2.01% |
| EPS CAGR 5y | 5.04% | 6.12% |
| Debt / Equity | - | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
INDV leads on
- Revenue CAGR 5y11.87%vs 2.01%+83%
- ROIC (TTM)85.68%vs 36.09%+58%
- Gross margin83.11%vs 57.79%+30%
- P/E (TTM)19.0xvs 25.3x+25%
MTD leads on
- Debt / Equity-vs -+93%
- Market cap$22.29Bvs $4.68B+79%
- EPS CAGR 5y6.12%vs 5.04%+18%
- Net margin21.4%vs 19.44%+9%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.